Literature DB >> 19663648

Targeting the IGF1 axis in cancer proliferation.

Ilan Bruchim1, Zohar Attias, Haim Werner.   

Abstract

The IGF network of ligands, cell-surface receptors and IGF-binding proteins has important roles at multiple levels, including the cellular, organ and organism levels. The IGF system mediates growth, differentiation and developmental processes, and is also involved in various metabolic activities. Dysregulation of IGF system expression and action is linked to diverse pathologies, ranging from growth deficits to cancer development. Targeting of the IGF axis emerged in recent years as a promising therapeutic approach in conditions in which the IGF system is involved. Specific IGF1 receptor (IGF1R) targeting, in particular, produced the best experimental and clinical results so far, and generated significant optimism in the field. This review provides a basic analysis of the role of the IGF1R in cancer biology and explores the functional interactions between the IGF signaling pathways and various cancer genes (e.g., oncogenes, tumor suppressors). In addition, we review a number of specific malignancies in which the IGF system is involved and summarize recent data on preclinical and clinical studies employing IGF1R-targeted modalities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19663648     DOI: 10.1517/14728220903201702

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  40 in total

1.  Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.

Authors:  Jilong Yang; Antti Ylipää; Yan Sun; Hong Zheng; Kexin Chen; Matti Nykter; Jonathan Trent; Nancy Ratner; Dina C Lev; Wei Zhang
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

Review 2.  Roles for growth factors in cancer progression.

Authors:  Esther Witsch; Michael Sela; Yosef Yarden
Journal:  Physiology (Bethesda)       Date:  2010-04

3.  Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R).

Authors:  William Engen; Terrence E O'Brien; Brendan Kelly; Jacinda Do; Liezel Rillera; Lance K Stapleton; Jack F Youngren; Marc O Anderson
Journal:  Bioorg Med Chem       Date:  2010-06-25       Impact factor: 3.641

Review 4.  Radioimmunotherapy of solid tumors: searching for the right target.

Authors:  Hong Song; George Sgouros
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

5.  Retracted: Involvement of insulin-like growth factor-1 in chemotherapy-related cognitive impairment.

Authors:  Teresita L Briones; Julie Woods; Magdalena Wadowska
Journal:  Behav Brain Res       Date:  2014-03-12       Impact factor: 3.332

6.  Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas.

Authors:  Paolo A Zucali; Iacopo Petrini; Elena Lorenzi; Maria Merino; Liang Cao; Luca Di Tommaso; Hye Seung Lee; Matteo Incarbone; Beatriz A Walter; Matteo Simonelli; Massimo Roncalli; Armando Santoro; Giuseppe Giaccone
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

7.  Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells.

Authors:  Rive Sarfstein; Metsada Pasmanik-Chor; Adva Yeheskel; Liat Edry; Noam Shomron; Naama Warman; Efrat Wertheimer; Sharon Maor; Lea Shochat; Haim Werner
Journal:  J Biol Chem       Date:  2011-11-29       Impact factor: 5.157

Review 8.  Insulin-like growth factor system and sporadic malignant melanoma.

Authors:  Ettore Capoluongo
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

9.  Molecular imaging of insulin-like growth factor 1 receptor in cancer.

Authors:  Yin Zhang; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

10.  Basic and clinical significance of IGF-I-induced signatures in cancer.

Authors:  Haim Werner; Ilan Bruchim
Journal:  BMC Med       Date:  2010-01-05       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.